Evaluation of a radiocobalt-labelled affibody molecule for imaging of human epidermal growth factor receptor 3 expression

Rosestedt,Maria; Andersson,Ken G.; Mitran,Bogdan; Rinne,Sara S.; Tolmachev,Vladimir; Löfblom,John; Orlova,Anna; Ståhl,Stefan

doi:10.3892/ijo.2017.4152

Evaluation of a radiocobalt-labelled affibody molecule for imaging of human epidermal growth factor receptor 3 expression

Authors:
- Maria Rosestedt
- Ken G. Andersson
- Bogdan Mitran
- Sara S. Rinne
- Vladimir Tolmachev
- John Löfblom
- Anna Orlova
- Stefan Ståhl
View Affiliations

Affiliations: Division of Molecular Imaging, Department of Medicinal Chemistry, Uppsala University, 751 83 Uppsala, Sweden, Division of Protein Technology, KTH - Royal Institute of Technology, SE-106 91 Stockholm, Sweden, Department of Immunology, Genetics and Pathology, Uppsala University, 751 83 Uppsala, Sweden
Published online on: October 11, 2017 https://doi.org/10.3892/ijo.2017.4152
Pages: 1765-1774

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The human epidermal growth factor receptor 3 (HER3) is involved in the development of cancer resistance towards tyrosine kinase-targeted therapies. Several HER3‑targeting therapeutics are currently under clinical evaluation. Non-invasive imaging of HER3 expression could improve patient management. Affibody molecules are small engineered scaffold proteins demonstrating superior properties as targeting probes for molecular imaging compared with monoclonal antibodies. Feasibility of in vivo HER3 imaging using affibody molecules has been previously demonstrated. Preclinical studies have shown that the contrast when imaging using anti-HER3 affibody molecules can be improved over time. We aim to develop an agent for PET imaging of HER3 expression using the long-lived positron-emitting radionuclide cobalt-55 (55Co) (T1/2=17.5 h). A long-lived cobalt isotope 57Co was used as a surrogate for 55Co in this study. The anti-HER3 affibody molecule HEHEHE-ZHER3-NOTA was labelled with radiocobalt with high yield, purity and stability. Biodistribution of 57Co-HEHEHE-ZHER3-NOTA was measured in mice bearing DU145 (prostate carcinoma) and LS174T (colorectal carcinoma) xenografts at 3 and 24 h post injection (p.i.). Tumour-to-blood ratios significantly increased between 3 and 24 h p.i. (p<0.05). At 24 h p.i., tumour-to-blood ratios were 6 for DU145 and 8 for LS174T xenografts, respectively. HER3‑expressing xenografts were clearly visualized in a preclinical imaging setting already 3 h p.i., and contrast further improved at 24 h p.i. In conclusion, the radiocobalt-labelled anti-HER3 affibody molecule, HEHEHE-ZHER3-NOTA, is a promising tracer for imaging of HER3 expression in tumours.

View Figures

View References

1	Baselga J and Swain SM: Novel anticancer targets: Revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer. 9:463–475. 2009. View Article : Google Scholar : PubMed/NCBI
2	Malm M, Frejd FY, Ståhl S and Löfblom J: Targeting HER3 using mono- and bispecific antibodies or alternative scaffolds. MAbs. 8:1195–1209. 2016. View Article : Google Scholar : PubMed/NCBI
3	Claus J, Patel G, Ng T and Parker PJ: A role for the pseudokinase HER3 in the acquired resistance against EGFR- and HER2-directed targeted therapy. Biochem Soc Trans. 42:831–836. 2014. View Article : Google Scholar : PubMed/NCBI
4	Gala K and Chandarlapaty S: Molecular pathways: HER3 targeted therapy. Clin Cancer Res. 20:1410–1416. 2014. View Article : Google Scholar : PubMed/NCBI
5	Amin DN, Campbell MR and Moasser MM: The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeutics. Semin Cell Dev Biol. 21:944–950. 2010. View Article : Google Scholar : PubMed/NCBI
6	Ma J, Lyu H, Huang J and Liu B: Targeting of erbB3 receptor to overcome resistance in cancer treatment. Mol Cancer. 13:1052014. View Article : Google Scholar : PubMed/NCBI
7	Mellinghoff IK, Vivanco I, Kwon A, Tran C, Wongvipat J and Sawyers CL: HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability. Cancer Cell. 6:517–527. 2004. View Article : Google Scholar : PubMed/NCBI
8	Leung HY, Weston J, Gullick WJ and Williams G: A potential autocrine loop between heregulin-alpha and erbB-3 receptor in human prostatic adenocarcinoma. Br J Urol. 79:212–216. 1997. View Article : Google Scholar : PubMed/NCBI
9	Soler M, Mancini F, Meca-Cortés O, Sánchez-Cid L, Rubio N, López-Fernández S, Lozano JJ, Blanco J, Fernández PL and Thomson TM: HER3 is required for the maintenance of neuregulin-dependent and -independent attributes of malignant progression in prostate cancer cells. Int J Cancer. 125:2565–2575. 2009. View Article : Google Scholar : PubMed/NCBI
10	Poovassery JS, Kang JC, Kim D, Ober RJ and Ward ES: Antibody targeting of HER2/HER3 signaling overcomes heregulin-induced resistance to PI3K inhibition in prostate cancer. Int J Cancer. 137:267–277. 2015. View Article : Google Scholar
11	Huang Z, Brdlik C, Jin P and Shepard HM: A pan-HER approach for cancer therapy: Background, current status and future development. Expert Opin Biol Ther. 9:97–110. 2009. View Article : Google Scholar
12	Dote H, Cerna D, Burgan WE, Camphausen K and Tofilon PJ: ErbB3 expression predicts tumor cell radiosensitization induced by Hsp90 inhibition. Cancer Res. 65:6967–6975. 2005. View Article : Google Scholar : PubMed/NCBI
13	Kol A, Terwisscha van Scheltinga AG, Timmer-Bosscha H, Lamberts LE, Bensch F, de Vries EG and Schröder CP: HER3, serious partner in crime: Therapeutic approaches and potential biomarkers for effect of HER3-targeting. Pharmacol Ther. 143:1–11. 2014. View Article : Google Scholar : PubMed/NCBI
14	Liu JF, Ray-Coquard I, Selle F, Poveda AM, Cibula D, Hirte H, Hilpert F, Raspagliesi F, Gladieff L, Harter P, et al: Randomized phase II Trial of seribantumab in combination with paclitaxel in patients with advanced platinum-resistant or -refractory ovarian cancer. J Clin Oncol. 34:4345–4353. 2016. View Article : Google Scholar : PubMed/NCBI
15	Di Cosimo S and Baselga J: Management of breast cancer with targeted agents: Importance of heterogeneity. [corrected]. Nat Rev Clin Oncol. 7:139–147. 2010. View Article : Google Scholar : PubMed/NCBI
16	Tolmachev V, Stone-Elander S and Orlova A: Radiolabelled receptor-tyrosine-kinase targeting drugs for patient stratification and monitoring of therapy response: Prospects and pitfalls. Lancet Oncol. 11:992–1000. 2010. View Article : Google Scholar : PubMed/NCBI
17	Pecking AP, Bellet D and Alberini JL: Immuno-SPET/CT and immuno-PET/CT: A step ahead to translational imaging. Clin Exp Metastasis. 29:847–852. 2012. View Article : Google Scholar : PubMed/NCBI
18	Robinson MK, Hodge KM, Horak E, Sundberg AL, Russeva M, Shaller CC, von Mehren M, Shchaveleva I, Simmons HH, Marks JD, et al: Targeting ErbB2 and ErbB3 with a bispecific single-chain Fv enhances targeting selectivity and induces a therapeutic effect in vitro. Br J Cancer. 99:1415–1425. 2008. View Article : Google Scholar : PubMed/NCBI
19	Tolmachev V, Tran TA, Rosik D, Abrahmsén L, Sjöberg A and Orlova A: Tumor targeting using Affibody molecules: An interplay of a target expression level, affinity and binding site composition. J Nucl Med. 53:953–960. 2012. View Article : Google Scholar : PubMed/NCBI
20	Terwisscha van Scheltinga AG, Lub-de Hooge MN, Abiraj K, Schröder CP, Pot L, Bossenmaier B, Thomas M, Hölzlwimmer G, Friess T, Kosterink JG, et al: ImmunoPET and biodistribution with human epidermal growth factor receptor 3 targeting antibody ⁸⁹Zr-Rg7116. MAbs. 6:1051–1058. 2014. View Article : Google Scholar : PubMed/NCBI
21	Yuan Q, Furukawa T, Tashiro T, Okita K, Jin ZH, Aung W, Sugyo A, Nagatsu K, Endo H, Tsuji AB, et al: Immuno-PET imaging of HER3 in a model in which HER3 signaling plays a critical role. PLoS One. 10:e01430762015. View Article : Google Scholar : PubMed/NCBI
22	Tolmachev V, Rosik D, Wållberg H, Sjöberg A, Sandström M, Hansson M, Wennborg A and Orlova A: Imaging of EGFR expression in murine xenografts using site-specifically labelled anti-EGFR ¹¹¹In-DOTA-Z EGFR:2377 affibody molecule: Aspect of the injected tracer amount. Eur J Nucl Med Mol Imaging. 37:613–622. 2010. View Article : Google Scholar
23	Orlova A, Magnusson M, Eriksson TL, Nilsson M, Larsson B, Höidén-Guthenberg I, Widström C, Carlsson J, Tolmachev V, Ståhl S, et al: Tumor imaging using a picomolar affinity HER2 binding affibody molecule. Cancer Res. 66:4339–4348. 2006. View Article : Google Scholar : PubMed/NCBI
24	Orlova A, Hofström C, Strand J, Varasteh Z, Sandstrom M, Andersson K, Tolmachev V and Gräslund T: [^99mTc(CO)3]⁺-(HE)₃-ZIGF1R:4551, a new affibody conjugate for visualization of insulin-like growth factor-1 receptor expression in malignant tumours. Eur J Nucl Med Mol Imaging. 40:439–449. 2013. View Article : Google Scholar
25	Ståhl S, Gräslund T, Eriksson Karlström A, Frejd FY, Nygren PÅ and Löfblom J: Affibody molecules in biotechnological and medical applications. Trends Biotechnol. 35:691–712. 2017. View Article : Google Scholar : PubMed/NCBI
26	Ahlgren S and Tolmachev V: Radionuclide molecular imaging using affibody molecules. Curr Pharm Biotechnol. 11:581–589. 2010. View Article : Google Scholar : PubMed/NCBI
27	Sörensen J, Sandberg D, Sandström M, Wennborg A, Feldwisch J, Tolmachev V, Åström G, Lubberink M, Garske-Román U, Carlsson J, et al: First-in-human molecular imaging of HER2 expression in breast cancer metastases using the ¹¹¹In-ABY-025 affibody molecule. J Nucl Med. 55:730–735. 2014. View Article : Google Scholar
28	Sörensen J, Velikyan I, Sandberg D, Wennborg A, Feldwisch J, Tolmachev V, Orlova A, Sandström M, Lubberink M, Olofsson H, et al: Measuring HER2-receptor expression in metastatic breast cancer using [⁶⁸Ga]ABY-025 affibody PET/CT. Theranostics. 6:262–271. 2016. View Article : Google Scholar
29	Malm M, Kronqvist N, Lindberg H, Gudmundsdotter L, Bass T, Frejd FY, Höidén-Guthenberg I, Varasteh Z, Orlova A, Tolmachev V, et al: Inhibiting HER3-mediated tumor cell growth with affibody molecules engineered to low picomolar affinity by position-directed error-prone PCR-like diversification. PLoS One. 8:e627912013. View Article : Google Scholar : PubMed/NCBI
30	Kronqvist N, Malm M, Göstring L, Gunneriusson E, Nilsson M, Höidén Guthenberg I, Gedda L, Frejd FY, Ståhl S and Löfblom J: Combining phage and staphylococcal surface display for generation of ErbB3-specific affibody molecules. Protein Eng Des Sel. 24:385–396. 2011. View Article : Google Scholar
31	Orlova A, Malm M, Rosestedt M, Varasteh Z, Andersson K, Selvaraju RK, Altai M, Honarvar H, Strand J, Ståhl S, et al: Imaging of HER3-expressing xenografts in mice using a (99mTc(CO)₃-HEHEHE-Z_HER3:08699 affibody molecule. Eur J Nucl Med Mol Imaging. 41:1450–1459. 2014. View Article : Google Scholar : PubMed/NCBI
32	Bass TZ, Rosestedt M, Mitran B, Frejd FY, Löfblom J, Tolmachev V, Ståhl S and Orlova A: In vivo evaluation of a novel format of a bivalent HER3-targeting and albumin-binding therapeutic affibody construct. Sci Rep. 7:431182017. View Article : Google Scholar : PubMed/NCBI
33	Orlova A, Bass T, Atterby C, Gudmundsdotter L, Frejd FY, Löfblom J, Tolmachev V and Ståhl S: Evaluating the therapeutic potential of a dimeric HER3-binding affibody construct in comparison with a monoclonal antibody, seribantumab. Affibody Molecules Targeting HER3 for Cancer Therapy. Bass T: Royal Institute of Technology, School of Biotechnology; Stockholm: 2017
34	Andersson KG, Rosestedt M, Varasteh Z, Malm M, Sandström M, Tolmachev V, Löfblom J, Ståhl S and Orlova A: Comparative evaluation of ¹¹¹In-labeled NOTA conjugated affibody molecules for visualization of HER3 expression in malignant tumors. Oncol Rep. 34:1042–1048. 2015. View Article : Google Scholar : PubMed/NCBI
35	Rosestedt M, Andersson KG, Mitran B, Tolmachev V, Löfblom J, Orlova A and Ståhl S: Affibody-mediated PET imaging of HER3 expression in malignant tumours. Sci Rep. 5:152262015. View Article : Google Scholar : PubMed/NCBI
36	Da Pieve C, Allott L, Martins CD, Vardon A, Ciobota DM, Kramer-Marek G and Smith G: Efficient [(18)F]AlF radiolabeling of Z_HER3:8698 affibody molecule for imaging of HER3 positive tumors. Bioconjug Chem. 27:1839–1849. 2016. View Article : Google Scholar : PubMed/NCBI
37	Fani M, André JP and Maecke HR: ⁶⁸Ga-PET: A powerful generator-based alternative to cyclotron-based PET radiopharmaceuticals. Contrast Media Mol Imaging. 3:67–77. 2008. View Article : Google Scholar : PubMed/NCBI
38	Thisgaard H, Olesen ML and Dam JH: Radiosynthesis of ⁵⁵Co- and ^58mCo-labelled DOTATOC for positron emission tomography imaging and targeted radionuclide therapy. J Labelled Comp Radiopharm. 54:758–762. 2011. View Article : Google Scholar
39	Jansen HM, Willemsen AT, Sinnige LG, Paans AM, Hew JM, Franssen EJ, Zorgdrager AM, Pruim J, Minderhoud JM and Korf J: Cobalt-55 positron emission tomography in relapsing-progressive multiple sclerosis. J Neurol Sci. 132:139–145. 1995. View Article : Google Scholar : PubMed/NCBI
40	Jansen HM, Pruim J, vd Vliet AM, Paans AM, Hew JM, Franssen EJ, de Jong BM, Kosterink JG, Haaxma R and Korf J: Visualization of damaged brain tissue after ischemic stroke with cobalt-55 positron emission tomography. J Nucl Med. 35:456–460. 1994.PubMed/NCBI
41	Wållberg H, Ahlgren S, Widström C and Orlova A: Evaluation of the radiocobalt-labeled [MMA-DOTA-Cys⁶¹]-Z_HER2:2395(-Cys) affibody molecule for targeting of HER2-expressing tumors. Mol Imaging Biol. 12:54–62. 2010. View Article : Google Scholar
42	Mitran B, Thisgaard H, Rosenström U, Dam JH, Larhed M, Tolmachev V and Orlova A: High contrast PET imaging of GRPR expression in prostate cancer using cobalt-labeled bombesin antagonist RM26. Contrast Media Mol Imaging. Aug 10–2017.Epub ahead of print. View Article : Google Scholar : PubMed/NCBI
43	Garousi J, Anderson KG, Dam JH, Olsen BB, Mitran B, Orlova A, Buijs J, Ståhl S, Löfblom J, Thisgaard H, et al: The use of radiocobalt as a label improves imaging of EGFR using DOTA-conjugated affibody molecule. Sci Rep. 7:59612017. View Article : Google Scholar : PubMed/NCBI
44	Wållberg H and Orlova A: Slow internalization of anti-HER2 synthetic affibody monomer ¹¹¹In-DOTA-Z_{HER2:342-pep2}: Implications for development of labeled tracers. Cancer Biother Radiopharm. 23:435–442. 2008. View Article : Google Scholar
45	Nestor M, Sundström M, Anniko M and Tolmachev V: Effect of cetuximab in combination with alpha-radioimmunotherapy in cultured squamous cell carcinomas. Nucl Med Biol. 38:103–112. 2011. View Article : Google Scholar : PubMed/NCBI
46	Björkelund H, Gedda L, Malmqvist M and Andersson K: Resolving the EGF-EGFR interaction characteristics through a multiple-temperature, multiple-inhibitor, real-time interaction analysis approach. Mol Clin Oncol. 1:343–352. 2013. View Article : Google Scholar
47	Schoeberl B, Faber AC, Li D, Liang MC, Crosby K, Onsum M, Burenkova O, Pace E, Walton Z, Nie L, et al: An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation. Cancer Res. 70:2485–2494. 2010. View Article : Google Scholar : PubMed/NCBI
48	Jansen HM, Knollema S, van der Duin LV, Willemsen AT, Wiersma A, Franssen EJ, Russel FG, Korf J and Paans AM: Pharmacokinetics and dosimetry of cobalt-55 and cobalt-57. J Nucl Med. 37:2082–2086. 1996.PubMed/NCBI
49	Hofström C, Altai M, Honarvar H, Strand J, Malmberg J, Hosseinimehr SJ, Orlova A, Gräslund T and Tolmachev V: HAHAHA, HEHEHE, HIHIHI, or HKHKHK: Influence of position and composition of histidine containing tags on biodistribution of [(99m)Tc(CO)₃](+)-labeled affibody molecules. J Med Chem. 56:4966–4974. 2013. View Article : Google Scholar
50	Wehrenberg-Klee E, Turker NS, Chang B, Heidari P and Mahmood U: Development of a HER3 PET probe for breast cancer imaging. J Nucl Med. 55(Suppl 1): s5502014.
51	Wehrenberg-Klee E, Turker NS, Heidari P, Larimer B, Juric D, Baselga J, Scaltriti M and Mahmood U: Differential receptor tyrosine kinase PET imaging for therapeutic guidance. J Nucl Med. 57:1413–1419. 2016. View Article : Google Scholar : PubMed/NCBI
52	Larimer BM, Phelan N, Wehrenberg-Klee E and Mahmood U: Phage display selection, in vitro characterization, and correlative PET imaging of a novel HER3 peptide. Mol Imaging Biol. Jul 21–2017.Epub ahead of print. View Article : Google Scholar : PubMed/NCBI
53	Garrett JT, Olivares MG, Rinehart C, Granja-Ingram ND, Sánchez V, Chakrabarty A, Dave B, Cook RS, Pao W, McKinely E, et al: Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase. Proc Natl Acad Sci USA. 108:5021–5026. 2011. View Article : Google Scholar : PubMed/NCBI